Nordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway

Denmark concentrates the densest Nordic biotech cluster in the Medicon Valley region around Copenhagen. Novo Nordisk Kalundborg is the anchor pharma manufacturer — one of the largest pharmaceutical manufacturing sites in Europe, with insulin and GLP-1 production at global commercial scale. Lundbeck (H. Lundbeck A/S) in Copenhagen runs CNS and psychiatric therapeutics. Genmab in Copenhagen runs an antibody-therapeutics platform with commercial-stage products and a deep oncology pipeline. The Danish biologics CDMO layer holds FUJIFILM Diosynth Biotechnologies Denmark (Hillerod, acquired from Biogen in 2019) and AGC Biologics Denmark (Soborg) — both operating at commercial scale. The Nordic vaccine + immunotherapy layer concentrates in Denmark: Bavarian Nordic (Kvistgaard) operates the MVA-BN smallpox/monkeypox/biodefence platform; ALK-Abelló (Horsholm) runs allergen immunotherapy manufacturing; Statens Serum Institut (Copenhagen) operates as the national vaccine + public-health reference institute. Smaller Danish biotechs (IO Biotech, MinervaX, Fuse Vectors, ExpreS2ion, Gubra, Novonesis, Visiopharm) round out the cluster.

Sweden is the largest Nordic biotech country in the directory with 43 operators. The Stockholm / Solna cluster sits adjacent to Karolinska Institutet and Karolinska University Hospital, with Affibody (protein therapeutics), Elypta (cancer diagnostics), Biosergen (anti-infectives), Sobi (rare-disease therapeutics at commercial scale), Oncopeptides (multiple myeloma therapeutics), Valneva Sweden (infectious-disease vaccines), Recipharm (CDMO), and an adjacent academic-translational layer. Lund concentrates therapeutics: Hansa Biopharma (enzyme-based transplant medicine at commercial scope with IdeS), Xintela (stem cell therapy + ATMP), Active Biotech (oncology + immunology). Uppsala is the Swedish bioprocess + diagnostics hub: Uppsala University anchors the research layer, Orexo runs specialty pharma, and Abera Bioscience operates nasal-vaccine platforms. Gothenburg hosts AstraZeneca Gothenburg (global R&D site), Elicera Therapeutics (immuno-oncology + CAR-T + oncolytic viruses), and Verigraft (tissue engineering ATMP). Umeå adds a northern Swedish cluster (Lipum, Lipigon, Nordic Biomarker, InfiCure Bio).

Finland holds 31 operators anchored by Orion Corporation in Espoo — the Finnish domestic large-pharma operator with CNS, oncology, respiratory, and veterinary therapeutics across commercial scale. Around Orion, Finland hosts a specialised CDMO + research cluster. Turku anchors the drug-discovery + radiopharma + 3PBIOVIAN biologics CDMO layer. Kuopio concentrates viral-vector manufacturing (FinVector, Kuopio Center for Gene and Cell Therapy) plus Rokote Laboratories (nasal adenoviral vaccine programmes). Helsinki adds Nanoform (nanoform particle engineering CDMO), Valo Therapeutics (oncolytic viruses + cancer immunotherapy), Abo Akademi-linked research, and multiple smaller biotechs. Oulu adds the ADMET + CDMO services layer (Admescope, Paras Biopharmaceuticals, Pharmatory). Tampere has StemSight (iPSC corneal cell therapy). Espoo’s Otaniemi campus hosts a deep-tech biotech layer + VTT Technical Research Centre.

Norway holds the smallest Nordic biotech count (17 operators, with Targovax and PCI Biotech retired and redirecting to the Nordics hub) but concentrates specialised therapeutics + diagnostics around Oslo. Nykode Therapeutics (formerly Vaccibody, Oslo) operates a DNA-vaccine and immunotherapy platform. Zelluna ASA (Oslo) runs off-the-shelf TCR-NK cell therapy for solid tumors. Photocure (Oslo) operates Hexvix / Cysview for bladder-cancer diagnostics at commercial scale. The operating Norwegian biotech layer is narrower than Sweden or Denmark, but the Oslo immuno-oncology and cancer-diagnostics concentration is the Norwegian specialism the directory surfaces.

Nordic biotech operates through dense urban clusters rather than distributed networks. Medicon Valley (Copenhagen ↔ Malmö / Lund across the Øresund bridge) is the largest cross-border Nordic biotech region, with Novo Nordisk, Genmab, Lundbeck, Hansa Biopharma, and the full Danish CDMO + vaccine layer all within 30-km catchment. The Karolinska cluster in Solna / Stockholm anchors Swedish translational and clinical-stage biotech — Affibody, Elypta, Biosergen, Sobi, Oncopeptides, plus dozens of smaller operators. Uppsala is Sweden’s bioprocess + diagnostics town. Lund is Sweden’s southern therapeutics city (Hansa, Active Biotech, Xintela). Gothenburg anchors AstraZeneca-led research + Elicera / Verigraft. In Finland, Turku is the drug-discovery + CDMO belt and Kuopio the viral-vector hub. Oslo concentrates Norwegian immunotherapy + diagnostics. For sponsors, picking the right Nordic city matters as much as picking the right country.

Denmark, Sweden, and Finland are EU member states. Norway is an EEA member operating under the same single-market framework for pharmaceutical trade and clinical trials (CTIS, EMA). GDP-certified logistics run through the same pan-European operators covering Germany and the Baltics — DHL Life Sciences & Healthcare, Kuehne+Nagel Healthcare, and World Courier. FUJIFILM Diosynth Denmark and AGC Biologics Denmark provide Nordic-based biologics CDMO capacity that complements German and Swiss alternatives (see Swiss vs German Biotech Manufacturing 2026 and European CDMO Capacity 2026 briefs). For sponsors building a pan-European footprint, the Nordic layer is the natural complement to German and Baltic capacity — mature pharma + vaccine innovation on top of an EU-aligned regulatory framework.

Match the decision to the need. Large pharma manufacturing + commercial scale: Novo Nordisk Kalundborg (if you can engage) or Orion Espoo. Biologics CDMO: FUJIFILM Diosynth Denmark or AGC Biologics Denmark. Vaccines + biodefence: Bavarian Nordic. Allergen immunotherapy: ALK-Abelló. Antibody-therapeutics pipeline partnerships: Genmab. Rare-disease therapeutics partnerships: Sobi or Hansa Biopharma. mRNA / particle-engineering CDMO: Nanoform Helsinki. Viral-vector CDMO: FinVector Kuopio. ATMP / cell therapy: Xintela, Elicera Therapeutics, Valo Therapeutics, Zelluna ASA. Oncology diagnostics: Photocure or Elypta. Clinical services: CROs are lighter in the Nordics than in Germany or the Baltics — pan-European CROs (ICON, Medpace, Pratia) serve from regional offices. The European mRNA & Immunotherapy 2026 brief, the Viral Vector CDMO Europe 2026 brief, and the How to Pick a European Biotech Partner 2026 brief cover partner selection across modalities.